N-Acetylcysteine (NAC): History and Discovery

N-acetylcysteine has one of the clearest and best-documented histories of any compound on this site, because it is a man-made molecule with a paper trail rather than a plant gathered since antiquity. It began life in the laboratory around 1960 as a way to thin sticky mucus, reached the clinic as the inhaled drug Mucomyst in the early 1960s, and then — in one of the genuinely lucky turns in modern medicine — turned out to be a life-saving antidote for paracetamol (acetaminophen) overdose, work led by the Scottish physician Lawrence Prescott and published in 1977. This article tells what the documented record actually supports: what NAC is and how it relates to the amino acid cysteine, who first made and patented it, how it became a mucus-thinner and then a poisoning antidote, how scientists came to understand its link to the body's "master antioxidant" glutathione, and how a sixty-year-old drug became one of the most studied small molecules in medicine. Where a date or a name is firmly recorded we say so; where sources disagree on a detail we say that too.

Table of Contents

  1. What NAC Is: A Small Tweak to Cysteine
  2. Invention and Patent: Sheffner, 1960–1963
  3. Mucomyst: The Mucus-Thinning Drug
  4. The Paracetamol Antidote: Prescott, 1977
  5. Understanding Why It Works: The Glutathione Story
  6. From Drip to Capsule: Oral and IV Protocols
  7. An Old Drug With New Tricks
  8. Drug or Supplement? A Recent Tangle
  9. Research Papers and References
  10. Connections
  11. Featured Videos

What NAC Is: A Small Tweak to Cysteine

To understand NAC's history it helps to know what the molecule actually is, because the chemistry is the whole reason it exists. N-acetylcysteine — often written NAC, and also called acetylcysteine — is simply the amino acid cysteine with a small chemical group, an acetyl group, attached to its nitrogen end. That tiny change is what the "N-acetyl" in the name means. Cysteine itself is one of the building blocks of protein and carries a reactive sulfur-containing "thiol" group; the problem with plain cysteine is that it is unstable and easily oxidised. Capping it with the acetyl group makes the molecule far more stable and easier to handle as a medicine, while the body can later strip the cap off to release useful cysteine.

This relationship matters because cysteine is the hard-to-get ingredient the body needs to make glutathione, an antioxidant produced inside nearly every cell. As later sections explain, much of NAC's story is the gradual discovery that this stable, swallowable form of cysteine could be used to refill the body's glutathione tank. But none of that was the original goal. NAC was first made for a much more down-to-earth purpose: to break up thick mucus. The deeper biology came later, which is exactly why the history reads the way it does — a practical chemical invention whose most important uses were discovered, sometimes by accident, only afterward.

Back to Table of Contents

Invention and Patent: Sheffner, 1960–1963

Unlike a traditional herb, NAC has a documented inventor and a patent. The compound's mucus-thinning use was developed by the biochemist A. L. Sheffner, working for the American pharmaceutical company Mead Johnson & Company. Sheffner had shown in laboratory tests that N-acetylcysteine and related sulfur-containing compounds could lower the thickness of mucus by breaking the chemical cross-links (disulfide bonds) that make mucus stringy and stiff. This led to a United States patent — number 3,091,569, "Mucolytic-N-acylated sulfhydryl compositions and process for treating animal mucus" — covering NAC's use as a mucus-thinner. The application is generally dated to 1960 and the patent was granted in 1963. (Published sources differ on the exact grant date in 1963, so this page gives the year rather than a specific day.)

It is worth being precise about what was "invented" here. N-acetylcysteine as a chemical was not unknown, and no single person can be said to have created the cysteine molecule that underlies it. What Sheffner and Mead Johnson did, and what the patent records, was the discovery and commercial development of NAC as a medicine for thinning mucus — the specific application that brought the compound out of the laboratory and into hospitals. That is the firm, documented starting point of NAC's career as a drug.

Back to Table of Contents

Mucomyst: The Mucus-Thinning Drug

NAC reached patients under the brand name Mucomyst, an inhaled (nebulised) solution approved in the United States in 1963 as a mucolytic — literally, a mucus-dissolver. The idea behind it follows directly from the chemistry of the previous section. Mucus owes much of its stickiness to long protein chains held together by disulfide bonds; NAC's reactive thiol group snips those bonds, so the mucus becomes thinner and easier to cough up or clear. Breathed in as a fine mist, it was used to loosen the thick secretions that build up in conditions such as chronic bronchitis and cystic fibrosis, where clearing mucus is a constant struggle. Reviews note that NAC came into clinical use as a mucolytic through the later 1960s, with documented use in cystic fibrosis from around 1969.

Two features of the inhaled drug are part of its lasting reputation. The first is its smell: NAC has a strong sulfur, "rotten-egg" odour, an unavoidable consequence of that reactive sulfur group, which has always made it somewhat unpleasant to take. The second is a quirk that still matters clinically — in some people with asthma, inhaled NAC can irritate the airways and trigger bronchospasm, which is why it is given carefully in that setting. For roughly a decade after its launch, this mucus-thinning role was essentially the whole story of NAC. The discovery that transformed it from a useful respiratory drug into a life-saver was still to come.

Back to Table of Contents

The Paracetamol Antidote: Prescott, 1977

The turning point in NAC's history came from a different and urgent problem: poisoning by paracetamol (known in the United States as acetaminophen, the painkiller in Tylenol). Taken in overdose, paracetamol can destroy the liver, and through the early 1970s such overdoses were often fatal with no reliable treatment. The breakthrough rested on new understanding of why the drug was so toxic — the subject of the next section — which pointed researchers toward antidotes that could restore the liver's glutathione. Early candidates such as cysteamine and methionine showed promise but were poorly tolerated, causing flushing, vomiting and considerable misery.

The decisive step is firmly documented. In 1977, the Scottish clinical pharmacologist Lawrence (L. F.) Prescott and colleagues, working in Edinburgh, published a landmark report in the medical journal The Lancet titled "Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine." They gave NAC intravenously to poisoned patients and found that it gave near-complete protection against severe liver damage when started early — within roughly the first 8 to 10 hours after the overdose. Crucially, NAC was far better tolerated than the earlier antidotes and was already available as a sterile pharmaceutical solution. This is the moment a mucus-thinning drug became an antidote, and it remains the use for which NAC saves the most lives. To this day NAC is regarded as the standard treatment for paracetamol overdose and appears on the World Health Organization's List of Essential Medicines.

Back to Table of Contents

Understanding Why It Works: The Glutathione Story

The antidote did not appear out of nowhere; it grew from a piece of laboratory detective work that explains NAC's deepest connection to the body. In a celebrated series of papers in 1973 in the Journal of Pharmacology and Experimental Therapeutics, a team at the United States National Institutes of Health — Jerry Mitchell, David Jollow, William Potter, James Gillette, and Bernard Brodie — worked out how paracetamol poisons the liver. The body converts a small fraction of the drug into a highly reactive, toxic by-product (later named NAPQI). At ordinary doses this poison is quietly mopped up by glutathione. But in overdose the glutathione runs out — the team showed it could be driven down by 80 to 90 percent — and the unchecked poison then attacks liver cells. One paper in the series carried the revealing subtitle "protective role of glutathione."

That insight reframed the whole problem: the way to treat the poisoning was to refill the glutathione tank, and the limiting ingredient for making glutathione is cysteine. NAC, being a stable, deliverable form of cysteine, was an almost perfect fit. This is the thread that ties NAC's two great uses together. The same property that lets it restore liver glutathione in an overdose — supplying cysteine to rebuild the body's master antioxidant — is the property behind nearly every other use that has been explored since. In the language of pharmacology, NAC is a prodrug for cysteine and, through it, a precursor for glutathione. The fuller biochemistry, and the modern research into raising glutathione for general health, is covered on the main N-Acetylcysteine (NAC) page and in the Glutathione Precursor article.

Back to Table of Contents

From Drip to Capsule: Oral and IV Protocols

Prescott's original 1977 protocol gave NAC by intravenous drip. In the United States, where intravenous NAC was not yet approved, doctors instead developed an oral (by-mouth) protocol for paracetamol poisoning, building on a way of reading overdose risk known as the Rumack–Matthew nomogram, a graph first published in 1975 by Barry Rumack and Henry Matthew that uses the blood drug level and the time since ingestion to judge who needs treatment. The oral regimen was validated on a large scale in a study published in 1988 in the New England Journal of Medicine by Martin Smilkstein, Barry Rumack and colleagues, analysing a national multicentre experience of more than two thousand treated patients and establishing the loading-plus-maintenance oral dosing schedule.

The intravenous route eventually returned to the United States formally: the U.S. Food and Drug Administration approved an intravenous acetylcysteine product, Acetadote (Cumberland Pharmaceuticals), in January 2004 for paracetamol overdose. So the modern picture — a choice of an oral or an intravenous course, guided by a decades-old nomogram — is itself a layered piece of history, with the intravenous idea coming from Edinburgh in the 1970s and the oral approach refined in the United States across the 1970s and 1980s. Across all of these protocols the central message has never changed: the antidote works best the earlier it is given, which is why paracetamol overdose is treated as an emergency.

Back to Table of Contents

An Old Drug With New Tricks

Once it was understood that NAC could top up glutathione throughout the body — not just rescue the liver in an emergency — researchers began asking what else low glutathione might contribute to, and whether NAC could help. From the 1990s onward this turned a humble respiratory drug into one of the most heavily investigated small molecules in medicine. A widely cited 2007 review in Current Opinion in Pharmacology by Kondala Atkuri and the Stanford immunologists Leonard and Leonore Herzenberg captured the mood in its title: NAC was "a safe antidote for cysteine/glutathione deficiency," with the Herzenberg group's own work pointing to benefits in conditions marked by glutathione depletion, including HIV infection.

Since then NAC has been studied in respiratory disease (notably chronic obstructive pulmonary disease), liver disease beyond paracetamol poisoning, fertility and polycystic ovary syndrome, and a strikingly active line of psychiatric research, among others. A notable recent thread is the work of Rajagopal Sekhar and colleagues at Baylor College of Medicine on GlyNAC — glycine combined with NAC — reported in a randomised clinical trial in older adults in 2023, exploring whether restoring glutathione can improve markers tied to ageing. The honest framing matters here: a long and growing research record is a sign of serious scientific interest, not proof that NAC works for every use being tested. The detailed evidence, what is strong and what is preliminary, lives in the NAC Benefits articles; this history simply marks how a 1960s mucus-thinner became a compound studied across so much of medicine.

Back to Table of Contents

Drug or Supplement? A Recent Tangle

A final, distinctly modern chapter concerns NAC's legal status rather than its biology, and it is worth knowing because it has caused real confusion for ordinary people. For many years NAC was sold both as a prescription and hospital medicine and, in the United States, as an over-the-counter dietary supplement. Beginning around 2020, the U.S. Food and Drug Administration took the position that because NAC was first approved as a drug (back in 1963), it could not also be marketed as a dietary supplement — a stance rooted in the sequence of its history rather than in any new safety concern. For a time this created uncertainty, and some retailers pulled NAC supplements from their shelves.

The agency later said it intended to exercise "enforcement discretion," effectively allowing NAC supplements to continue being sold while the question was worked through. In much of Europe, by contrast, NAC has long been available over the counter as a mucolytic. The practical takeaway is that NAC's odd dual identity — simultaneously an old approved drug and a popular supplement — is a direct echo of where its story began: a compound that entered medicine as a patented pharmaceutical in 1963 and only decades later became a fixture of the supplement aisle.

Back to Table of Contents

Research Papers and References

The list below gathers the key primary sources behind the history above, together with one or two curated PubMed topic searches into the historical and mechanistic literature. Author names, titles, and journals are given as plain text; only the stable DOI, PMID, or archive link is hyperlinked, and each opens in a new tab.

  1. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N-acetylcysteine. Lancet. 1977;2(8035):432-434. — doi:10.1016/s0140-6736(77)90612-2 · PMID: 70646
  2. Mitchell JR, Jollow DJ, Potter WZ, Davis DC, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism. Journal of Pharmacology and Experimental Therapeutics. 1973;187(1):185-194. — PMID: 4746326
  3. Mitchell JR, Jollow DJ, Potter WZ, Gillette JR, Brodie BB. Acetaminophen-induced hepatic necrosis. IV. Protective role of glutathione. Journal of Pharmacology and Experimental Therapeutics. 1973;187(1):211-217. — PMID: 4746329
  4. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985). New England Journal of Medicine. 1988;319(24):1557-1562. — doi:10.1056/NEJM198812153192401 · PMID: 3059186
  5. Atkuri KR, Mantovani JJ, Herzenberg LA, Herzenberg LA. N-Acetylcysteine — a safe antidote for cysteine/glutathione deficiency. Current Opinion in Pharmacology. 2007;7(4):355-359. — doi:10.1016/j.coph.2007.04.005 · PMID: 17602868
  6. Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV. Supplementing Glycine and N-Acetylcysteine (GlyNAC) in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, physical function, and aging hallmarks: a randomized clinical trial. The Journals of Gerontology: Series A. 2023;78(1):75-89. — doi:10.1093/gerona/glac135
  7. N-acetylcysteine history and mucolytic origins — PubMed: NAC history and mucolytic use
  8. N-acetylcysteine and glutathione — mechanism — PubMed: NAC as a glutathione/cysteine precursor

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents